Vericel Co. (NASDAQ:VCEL) Director Sells $156,250.00 in Stock

Vericel Co. (NASDAQ:VCEL) Director Robert L. Md Zerbe sold 2,500 shares of the stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $62.50, for a total value of $156,250.00. Following the completion of the transaction, the director now owns 26,595 shares in the company, valued at $1,662,187.50. This represents a 8.59 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Vericel Stock Down 2.3 %

Shares of NASDAQ:VCEL opened at $58.35 on Monday. The company has a market cap of $2.88 billion, a price-to-earnings ratio of 972.66 and a beta of 1.72. The business has a 50 day moving average price of $57.84 and a 200 day moving average price of $51.15. Vericel Co. has a twelve month low of $39.12 and a twelve month high of $63.00.

Vericel (NASDAQ:VCEL) last posted its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.02) earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.03. Vericel had a return on equity of 1.48% and a net margin of 1.56%. The company had revenue of $57.91 million during the quarter, compared to analysts’ expectations of $55.32 million. Analysts anticipate that Vericel Co. will post 0.14 EPS for the current year.

Institutional Trading of Vericel

Hedge funds have recently bought and sold shares of the stock. Raymond James Financial Inc. acquired a new position in shares of Vericel during the fourth quarter valued at about $28,126,000. Geneva Capital Management LLC increased its stake in Vericel by 61.4% during the third quarter. Geneva Capital Management LLC now owns 1,104,386 shares of the biotechnology company’s stock valued at $46,660,000 after acquiring an additional 420,078 shares during the period. Wellington Management Group LLP increased its stake in Vericel by 214.0% during the third quarter. Wellington Management Group LLP now owns 587,857 shares of the biotechnology company’s stock valued at $24,837,000 after acquiring an additional 400,667 shares during the period. Congress Asset Management Co. raised its holdings in Vericel by 37.4% in the 3rd quarter. Congress Asset Management Co. now owns 1,291,720 shares of the biotechnology company’s stock valued at $54,575,000 after acquiring an additional 351,550 shares in the last quarter. Finally, TimesSquare Capital Management LLC lifted its position in shares of Vericel by 54.8% in the 3rd quarter. TimesSquare Capital Management LLC now owns 590,145 shares of the biotechnology company’s stock worth $24,934,000 after acquiring an additional 209,009 shares during the period.

Analysts Set New Price Targets

VCEL has been the topic of several analyst reports. Stephens restated an “overweight” rating and set a $65.00 price target on shares of Vericel in a research note on Wednesday, January 15th. Truist Financial increased their target price on shares of Vericel from $61.00 to $67.00 and gave the stock a “buy” rating in a research report on Wednesday, December 18th. HC Wainwright reaffirmed a “buy” rating and issued a $60.00 price target on shares of Vericel in a research report on Wednesday, January 15th. StockNews.com upgraded Vericel from a “sell” rating to a “hold” rating in a research note on Tuesday, December 24th. Finally, Canaccord Genuity Group raised their price objective on Vericel from $64.00 to $67.00 and gave the company a “buy” rating in a research note on Monday, February 3rd. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $63.14.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.